WallStreetZenWallStreetZen

NASDAQ: TCON
Tracon Pharmaceuticals Inc Stock

$0.18-0.01 (-5.26%)
Updated Feb 21, 2024
TCON Price
$0.18
Fair Value Price
$0.36
Market Cap
$5.64M
52 Week Low
$0.13
52 Week High
$2.19
P/E
-0.31x
P/B
-1.83x
P/S
0.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.00M
Earnings
-$11.02M
Gross Margin
100%
Operating Margin
-30.72%
Profit Margin
-122.5%
Debt to Equity
-4.05
Operating Cash Flow
-$455k
Beta
0.84
Next Earnings
Mar 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TCON Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TCON ($0.18) is undervalued by 50.35% relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TCON ($0.18) is significantly undervalued by 50.35% relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TCON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCON due diligence checks available for Premium users.

Be the first to know about important TCON news, forecast changes, insider trades & much more!

TCON News

Valuation

TCON fair value

Fair Value of TCON stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$0.36
Undervalued by
50.62%
TCON ($0.18) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCON ($0.18) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TCON price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.31x
Industry
16.04x
Market
28.8x

TCON price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.83x
Industry
5.97x

TCON's financial health

Profit margin

Revenue
$0.0
Net Income
$10.8M
Profit Margin
0%
TCON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCON's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$9.4M
Liabilities
$12.5M
Debt to equity
-4.05
TCON's short-term liabilities ($11.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCON's short-term assets ($8.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TCON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$15.1M
Investing
$0.0
Financing
-$9.1M
TCON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TCON vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TCON$5.64M-2.69%-0.31x-1.83x
MYMD$5.63M-11.23%-0.61x0.36x
GTBP$5.58M-8.80%-0.45x0.56x
TTNP$5.70M-5.03%-0.93x0.70x
HOTH$5.78M-1.48%-0.28x0.55x

Tracon Pharmaceuticals Stock FAQ

What is Tracon Pharmaceuticals's quote symbol?

(NASDAQ: TCON) Tracon Pharmaceuticals trades on the NASDAQ under the ticker symbol TCON. Tracon Pharmaceuticals stock quotes can also be displayed as NASDAQ: TCON.

If you're new to stock investing, here's how to buy Tracon Pharmaceuticals stock.

What is the 52 week high and low for Tracon Pharmaceuticals (NASDAQ: TCON)?

(NASDAQ: TCON) Tracon Pharmaceuticals's 52-week high was $2.19, and its 52-week low was $0.13. It is currently -91.74% from its 52-week high and 43.65% from its 52-week low.

How much is Tracon Pharmaceuticals stock worth today?

(NASDAQ: TCON) Tracon Pharmaceuticals currently has 31,144,335 outstanding shares. With Tracon Pharmaceuticals stock trading at $0.18 per share, the total value of Tracon Pharmaceuticals stock (market capitalization) is $5.64M.

Tracon Pharmaceuticals stock was originally listed at a price of $94.00 in Jan 30, 2015. If you had invested in Tracon Pharmaceuticals stock at $94.00, your return over the last 9 years would have been -99.81%, for an annualized return of -50.08% (not including any dividends or dividend reinvestments).

How much is Tracon Pharmaceuticals's stock price per share?

(NASDAQ: TCON) Tracon Pharmaceuticals stock price per share is $0.18 today (as of Feb 21, 2024).

What is Tracon Pharmaceuticals's Market Cap?

(NASDAQ: TCON) Tracon Pharmaceuticals's market cap is $5.64M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tracon Pharmaceuticals's market cap is calculated by multiplying TCON's current stock price of $0.18 by TCON's total outstanding shares of 31,144,335.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.